Showing results (511-520 of 782) with videos related to
Sort By:
Pageof 79
Blood|September 10, 2005
Dysfunctional T regulatory cells in multiple myelomaRao H Prabhala, Paola Neri, Jooeun E Bae, et al.Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.Oncotarget|October 21, 2016
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applicationsJana Jakubikova, Danka Cholujova, Teru Hideshima, et al.Cancer Research|December 18, 2003
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.Blood|November 20, 2008
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signalingMarc S Raab, Iris Breitkreutz, Giovanni Tonon, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
Novel therapies in the treatment of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.Cell Reports|July 21, 2015
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional ActivationAldo M Roccaro, Yuji Mishima, Antonio Sacco, et al.Blood|November 5, 2020
Progression signature underlies clonal evolution and dissemination of multiple myelomaYu Jia Shen, Yuji Mishima, Jiantao Shi, et al.Blood|March 25, 2016
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.Pageof 79